The final, formatted version of the article will be published soon.
REVIEW article
Front. Endocrinol.
Sec. Cancer Endocrinology
Volume 15 - 2024 |
doi: 10.3389/fendo.2024.1465727
This article is part of the Research Topic Obesity and Metabolism in Endocrine-Related Cancers View all articles
Obesity and Leptin in Breast Cancer Angiogenesis
Provisionally accepted
Courtney B. Lagarde
1,2
Kapil Thapa
3
Nicole M. Cullen
1,2
Mackenzie L. Hawes
1,2
Khudeja Salim
1,2
Megan C. Benz
1,2
Sophie R. Dietrich
1,2,4
Brandon E. Burow
3
Bruce A. Bunnell
5
Elizabeth C. Martin
1,2
Bridgette M. Collins-Burow
1,2
Ron Lynch
6
Van T. Hoang
1,2
Matthew Burow
1,2,7,8*
Jennifer Fang
3,9*- 1 Department of Medicine, Section of Hematology and Oncology, School of Medicine, Tulane University, New Orleans, United States
- 2 Tulane Cancer Center, School of Medicine, Tulane University, New Orleans, Louisiana, United States
- 3 Department of Cell and Molecular Biology, School of Science and Engineering, Tulane University, New Orleans, Louisiana, United States
- 4 Southern Regional Research Center, Agricultural Research Service (USDA), New Orleans, Louisiana, United States
- 5 Department of Microbiology, Immunology, and Genetics, University of North Texas Health Science Center, Fort Worth, Texas, United States
- 6 Department of Pharmacology, University of Arizona, Tucson, Arizona, United States
- 7 Department of Pharmacology, School of Medicine, Tulane University, New Orleans, Louisiana, United States
- 8 Department of Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, United States
- 9 Department of Physiology, School of Medicine, Tulane University, New Orleans, Louisiana, United States
At the time of breast cancer diagnosis, most patients meet the diagnostic criteria to be classified as obese or overweight. This can significantly impact patient outcome: breast cancer patients with obesity (body mass index > 30) have a poorer prognosis compared to patients with a lean BMI [1-3]. Obesity is associated with hyperleptinemia, and leptin is a well-established driver of metastasis in breast cancer [4,5]. However, the effect of hyperleptinemia on angiogenesis in breast cancer is less well-known. Angiogenesis is an important process in breast cancer because it is essential for tumor growth beyond 1mm 3 in size as well as cancer cell circulation and metastasis [6]. This review investigates the role of leptin in regulating angiogenesis, specifically within the context of breast cancer and the associated tumor microenvironment in obese patients.
Keywords: Leptin, Angiogenesis, breast cancer, Obesity, hyperleptinemia, Tumor Microenvironment
Received: 16 Jul 2024; Accepted: 04 Sep 2024.
Copyright: © 2024 Lagarde, Thapa, Cullen, Hawes, Salim, Benz, Dietrich, Burow, Bunnell, Martin, Collins-Burow, Lynch, Hoang, Burow and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Matthew Burow, Department of Medicine, Section of Hematology and Oncology, School of Medicine, Tulane University, New Orleans, United States
Jennifer Fang, Department of Cell and Molecular Biology, School of Science and Engineering, Tulane University, New Orleans, 70118, Louisiana, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.